Biogen (BUE:BIIB) Other Long-Term Liabilities

: ARS184,808 Mil (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Biogen's other long-term liabilities for the quarter that ended in Mar. 2023 was ARS184,808 Mil.

Biogen's quarterly other long-term liabilities declined from Sep. 2022 (ARS166,476 Mil) to Dec. 2022 (ARS158,295 Mil) but then increased from Dec. 2022 (ARS158,295 Mil) to Mar. 2023 (ARS184,808 Mil).

Biogen's annual other long-term liabilities increased from Dec. 2020 (ARS108,203 Mil) to Dec. 2021 (ARS133,357 Mil) and increased from Dec. 2021 (ARS133,357 Mil) to Dec. 2022 (ARS158,295 Mil).

Biogen Other Long-Term Liabilities Historical Data

The historical data trend for Biogen's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Long-Term Liabilities

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Other Long-Term Liabilities																-	-	-	-	-

Biogen Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Biogen Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.